See-Mode Technologies Receives Health Canada Approval for AI Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans

MELBOURNE,Australia,Nov. 17,2022 -- See-Mode Technologies,a MedTech company based in Australia that is on a mission to unlock the hidden insights within medical imaging,today announced that it has received approval from Health Canada for its product expansion to support Breast & Thyroid ultrasound examinations.

See-Mode uses Artificial Intelligence to detect lesions in ultrasound images,then assigns feature classifications to each lesion,in line with the American College of Radiology's BI-RADS and TI-RADS rating systems. Sonographer worksheets,complete with lesion classifications and diagrams are instantly generated and sent to PACS,while preliminary impressions are sent to radiology reporting systems. In follow-up scans,See-Mode allows for fast comparison between old and new images,and will automatically highlight changes in lesion characteristics.

"Receiving approval from Health Canada is a significant step forward for us at See-Mode,which demonstrates the applicability of our software beyond the vascular studies we currently support",said Dr Milad Mohammadzadeh,Co-Founder and Director,See-Mode Technologies. "Working closely with clinicians we learned that the reporting of Breast & Thyroid examinations was notoriously time consuming,subjective,and error prone,especially when there are multiple lesions present. We are excited to enable clinicians across Canada to complete their reports more efficiently and provide a second set of eyes on the study making sure nothing is missed."

"See-Mode represents a tremendous step forward by combining the power of Artificial Intelligence with the expertise of a clinical sonographer and radiologist. See-Mode eliminates tedious manual steps in the interpretation and reporting of ultrasound images,improves efficiency and provides unparalleled consistency of reporting between different members of the radiology team. This is a system that truly understands the content of ultrasound images." Martin Necas,Specialist Sonographer,Waikato Hospital,Clinical Consultant for See-Mode.

Studies conducted by See-Mode determined there were large inconsistencies in describing the characteristics of nodules and lesions by sonographers. For Thyroid studies,See-Mode has the potential toreduce unnecessary biopsies and improve the accuracy of the biopsies that are performed. With Breast ultrasound examinations,See-Mode assists clinicians to detect malignancy that may otherwise go undiscovered or misclassified.

About See-Mode Technologies

See-Mode applies cutting-edge deep learning and computational modeling techniques on medical images to empower clinicians to improve their clinical workflow and patient outcomes. See-Mode's first product,AVA,automatically analyses and reports on vascular ultrasound studies. AVAis currently clinically live across the US,Singapore,and New Zealand. See-Mode has offices in Singapore and Australia and is backed by prominent venture capital firms in APAC,including MassMutual Ventures,Blackbird Ventures,Cocoon Capital,and SGInnovate.